Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin Plus Sintilimab and S-1 for First-Line Treatment of HER2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
NCT06730373Phase 2Recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of disitamab vedotin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Objective Remission Rate at 6 months. Started Oct 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06730373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06730373.